Table 1 Baseline characteristics of patients and results of clinical trial
|  | FDG-PET/CT group (n = 65) | Standard CT group (n = 69) |  | ||
|---|---|---|---|---|---|
Characteristic | n | % | n | % | p-value |
Age median (range), years | 55 | (19–73) | 55 | (18–77) | 0.70 |
Female | 19 | 27.5 | 27 | 41.5 | 0.09 |
Primary underlying disease | Â | Â | Â | Â | 0.01 |
 Acute myeloid leukaemia | 38 | 58.5 | 33 | 47.8 |  |
 Acute lymphoblastic leukaemia | 3 | 4.6 | 13 | 18.8 |  |
 Myelodysplastic syndrome | 3 | 4.6 | 10 | 14.5 |  |
 Other | 21 | 32.3 | 13 | 18.8 |  |
Reason for admission | Â | Â | Â | Â | 0.23 |
 Chemotherapy | 34 | 52.3 | 29 | 42.0 |  |
 Transplant | 31 | 47.7 | 40 | 58.0 |  |
Age-adjusted Charlson Comorbidity Index median (IQR) | 3 | (2–4) | 3 | (2–4) | 0.89 |
Prior HSCT | 5 | 7.7 | 4 | 5.8 | 0.66 |
Outcomes | Â | Â | Â | Â | Â |
Antimicrobial rationalisation a | 53 | 81.5 | 45 | 65.2 | 0.03 |
Length of hospitalisation post scan mean (SD) | 15.4 | 15.3 | 17.3 | 16.4 | 0.50 |
Intensive care admission post scan | 6 | 9.2 | 9 | 13.0 | 0.48 |
6-month mortality | 8 | 12.5 | 10 | 14.7 | 0.71 |